US5086041A
(en)
*
|
1984-10-04 |
1992-02-04 |
Monsanto Company |
Methods of using prolonged release somatotropin compositions
|
US5411951A
(en)
*
|
1984-10-04 |
1995-05-02 |
Monsanto Company |
Prolonged release of biologically active somatotropin
|
KR890002631B1
(ko)
*
|
1984-10-04 |
1989-07-21 |
몬산토 캄파니 |
생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
|
US5474980A
(en)
*
|
1984-10-04 |
1995-12-12 |
Monsanto Company |
Prolonged release of biologically active somatotropins
|
US5037806A
(en)
*
|
1985-02-22 |
1991-08-06 |
Monsanto Company |
Biologically active method using somatotropins
|
US4775659A
(en)
*
|
1985-08-19 |
1988-10-04 |
Eli Lilly And Company |
Injectable semi-solid formulations
|
IL79765A
(en)
*
|
1985-08-23 |
1992-02-16 |
Lilly Co Eli |
Injectable sustained release formulations of bovine somatotropin
|
US4977140A
(en)
*
|
1985-08-23 |
1990-12-11 |
Eli Lilly And Company |
Injectable sustained release formulation
|
US4857506A
(en)
*
|
1987-01-12 |
1989-08-15 |
American Cyanamid Company |
Sustained release growth hormone compositions for parenteral administration and their use
|
EP0279616A3
(en)
*
|
1987-02-17 |
1990-03-07 |
International Minerals And Chemical Corporation |
Swine growth promotion
|
US4863736A
(en)
|
1987-03-16 |
1989-09-05 |
Monsanto Company |
Somatotropin prolonged release
|
GB8725427D0
(en)
*
|
1987-10-30 |
1987-12-02 |
Lilly Industries Ltd |
Somatotropin formulations
|
US5021554A
(en)
*
|
1989-02-24 |
1991-06-04 |
Eli Lilly And Company |
Process for protein particle size reduction using a fluid-energy mill
|
US5780599A
(en)
*
|
1990-07-13 |
1998-07-14 |
Novo Nordisk A/S |
Growth hormone crystals and a process for production of growth hormone crystals
|
DK168790D0
(zh)
*
|
1990-07-13 |
1990-07-13 |
Novo Nordisk As |
|
US6894023B1
(en)
|
1990-07-13 |
2005-05-17 |
Novo Nordisk A/S |
Growth hormone crystals and a process for production of these GH-crystals
|
YU87892A
(sh)
*
|
1991-10-01 |
1995-12-04 |
Eli Lilly And Company Lilly Corporate Center |
Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
|
US6063910A
(en)
*
|
1991-11-14 |
2000-05-16 |
The Trustees Of Princeton University |
Preparation of protein microparticles by supercritical fluid precipitation
|
DK0661989T3
(da)
*
|
1992-09-21 |
1998-03-02 |
Upjohn Co |
Proteinsammensætninger med vedvarende frigivelse
|
AU694419B2
(en)
*
|
1993-03-12 |
1998-07-23 |
Zoetis P&U Llc |
Crystalline ceftiofur free acid
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
ZA949350B
(en)
|
1994-01-25 |
1996-05-24 |
Upjohn Co |
Aqueous prolonged release formulation
|
ES2151079T3
(es)
*
|
1994-09-09 |
2000-12-16 |
Takeda Chemical Industries Ltd |
Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
|
CA2240685A1
(en)
|
1996-01-11 |
1997-07-17 |
Pharmacia & Upjohn Company |
Aqueous prolonged release formulation
|
US5767080A
(en)
*
|
1996-05-01 |
1998-06-16 |
Cargill, Incorporated |
Enhanced milk production in dairy cattle
|
KR20080011353A
(ko)
|
2000-02-24 |
2008-02-01 |
몬산토 테크놀로지 엘엘씨 |
소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
|
MXPA03000073A
(es)
*
|
2000-06-26 |
2003-09-25 |
Monsanto Technology Llc |
Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
|
US6664234B1
(en)
*
|
2000-06-30 |
2003-12-16 |
Monsanto Technology Llc |
Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
|
JP2004515467A
(ja)
|
2000-08-07 |
2004-05-27 |
ネクター セラピューティックス |
吸入可能な、噴霧乾燥した、最少の凝集物を有する4−ヘリックスバンドルタンパク質粉末
|
US7829100B2
(en)
*
|
2000-09-12 |
2010-11-09 |
Teagarden Dirk L |
Pharmaceutical composition having modified carrier
|
DE10161078A1
(de)
*
|
2001-12-12 |
2003-08-28 |
Achim Goepferich |
Matrizes zur Stabilisierung und kontrollierten Freisetzung von Problemarzneistoffen
|
US7659061B2
(en)
*
|
2002-11-19 |
2010-02-09 |
Pharmacia & Upjohn Company |
Pharmaceutical compositions having a modified vehicle
|
JP2006199589A
(ja)
*
|
2003-09-03 |
2006-08-03 |
Ltt Bio-Pharma Co Ltd |
生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
|
EP1866319B1
(en)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
GB0511269D0
(en)
|
2005-06-02 |
2005-07-13 |
Creative Peptides Sweden Ab |
Sustained release preparation of pro-insulin C-peptide
|
RU2457854C2
(ru)
|
2005-12-30 |
2012-08-10 |
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед |
Длительное высвобождение нейрегулина для улучшения сердечной функции
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
CA2644784A1
(en)
*
|
2006-03-13 |
2007-09-20 |
Jinling Chen |
Formulations of sitaxsentan sodium
|
CN101443314B
(zh)
*
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
作为gsk-3抑制剂的氨基喹诺酮类
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
EP2081893B1
(en)
|
2006-10-19 |
2011-03-23 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
WO2008057604A2
(en)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
|
PL2144604T3
(pl)
*
|
2007-02-28 |
2012-02-29 |
Conatus Pharmaceuticals Inc |
Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
DK2125698T3
(en)
|
2007-03-15 |
2016-11-07 |
Auspex Pharmaceuticals Inc |
Deuterated d9-VENLAFAXINE
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
CN101801188A
(zh)
*
|
2007-07-12 |
2010-08-11 |
特拉加拉医药品公司 |
治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
|
CN101855228B
(zh)
*
|
2007-09-11 |
2012-10-24 |
杏林制药株式会社 |
作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
|
EP2203459B1
(en)
|
2007-09-12 |
2016-03-16 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as gsk-3 inhibitors
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
CA2972138A1
(en)
|
2008-03-17 |
2009-09-24 |
Ambit Biosciences Corporation |
Raf kinase modulator compounds and methods of use thereof
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
AU2009249600A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Cerenis Therapeutics Holding S.A. |
Niacin and NSAID for combination therapy
|
CA2729168A1
(en)
|
2008-07-02 |
2010-02-04 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2324034A4
(en)
*
|
2008-08-22 |
2012-05-16 |
Orchid Chemicals & Pharm Ltd |
CRYSTALLINE SODIUM SALT OF CEPHALOSPORIN ANTIBIOTIC
|
WO2010076329A1
(en)
|
2008-12-31 |
2010-07-08 |
Scynexis, Inc. |
Derivatives of cyclosporin a
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
KR20110124787A
(ko)
|
2009-02-27 |
2011-11-17 |
암비트 바이오사이언시즈 코포레이션 |
Jak 키나아제 조절 퀴나졸린 유도체 및 이의 사용 방법
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
EP2406266B1
(en)
*
|
2009-03-11 |
2013-12-25 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as gsk-3 inhibitors
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
CN102448958B
(zh)
|
2009-03-27 |
2015-10-21 |
维特Dc公司 |
嘧啶基和1,3,5-三嗪基苯并咪唑磺酰胺和其在癌症治疗中的用途
|
EP2727908A3
(en)
|
2009-04-22 |
2014-08-20 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide CCR3 antagonists
|
NZ620092A
(en)
|
2009-04-22 |
2015-07-31 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide ccr3 agtagonists
|
NZ620074A
(en)
|
2009-04-22 |
2015-09-25 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
CA2767008C
(en)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
CA2767168C
(en)
|
2009-07-08 |
2019-04-09 |
Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
EP2467144A1
(en)
|
2009-07-24 |
2012-06-27 |
ViroLogik GmbH |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
CN102470127A
(zh)
|
2009-08-19 |
2012-05-23 |
埃姆比特生物科学公司 |
联芳基化合物和其使用方法
|
TW201120037A
(en)
*
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
RU2554087C2
(ru)
|
2009-12-18 |
2015-06-27 |
Айденикс Фармасьютикалз, Инк. |
5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
KR20120125610A
(ko)
|
2009-12-30 |
2012-11-16 |
싸이넥시스, 인크. |
시클로스포린 유사체
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
UA115523C2
(uk)
|
2010-02-05 |
2017-11-27 |
Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" |
Тверді форми макроциклічних інгібіторів кінази
|
NZ717149A
(en)
|
2010-02-11 |
2017-06-30 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same for treating various diseases
|
DK2542542T3
(en)
|
2010-03-02 |
2015-07-20 |
Axikin Pharmaceuticals Inc |
ISOTOPIC ENRICHED ARYL SULPHONAMIDE CCR3 ANTAGONISTS
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
TW201134820A
(en)
|
2010-03-17 |
2011-10-16 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
MX2012013879A
(es)
|
2010-06-01 |
2013-04-03 |
Biotheryx Inc |
Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
|
CN103153309A
(zh)
|
2010-06-01 |
2013-06-12 |
拜欧赛里克斯公司 |
使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
|
SG186229A1
(en)
|
2010-06-07 |
2013-01-30 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
US20130225615A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
US20130303533A1
(en)
|
2010-09-01 |
2013-11-14 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030894A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
AU2011296046B2
(en)
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
WO2012030948A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
ES2581840T3
(es)
|
2010-09-01 |
2016-09-07 |
Ambit Biosciences Corporation |
Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
JP2013543512A
(ja)
|
2010-10-11 |
2013-12-05 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
アリールスルホンアミドccr3アンタゴニストの塩
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2012078649A1
(en)
|
2010-12-06 |
2012-06-14 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US8809349B2
(en)
|
2011-01-10 |
2014-08-19 |
Infinity Pharmaceuticals, Inc. |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
CN107375293A
(zh)
|
2011-03-11 |
2017-11-24 |
细胞基因公司 |
利用3‑(5‑氨基‑2‑甲基‑4‑氧‑4h‑喹唑啉‑3‑基)‑哌啶‑2,6‑二酮治疗癌症的方法
|
WO2012135160A1
(en)
|
2011-03-28 |
2012-10-04 |
Pathway Therapeutics Inc. |
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
|
US20140088103A1
(en)
|
2011-03-28 |
2014-03-27 |
Mei Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
EP2691389A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
JP2014514295A
(ja)
|
2011-03-31 |
2014-06-19 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
BR112013033339A2
(pt)
|
2011-06-23 |
2016-08-16 |
Map Pharmaceuticals Inc |
análogos de fluorergolina
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
JP6027611B2
(ja)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
AU2012302197B2
(en)
|
2011-08-29 |
2016-01-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
EP2755983B1
(en)
|
2011-09-12 |
2017-03-15 |
Idenix Pharmaceuticals LLC. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
TWI650321B
(zh)
|
2011-10-14 |
2019-02-11 |
美商安比特生物科學公司 |
雜環化合物及其使用方法
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013095707A1
(en)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
CA2859175A1
(en)
|
2011-12-21 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Novel neuromodulatory compounds
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
EP2852586A1
(en)
|
2012-03-16 |
2015-04-01 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
SG11201407674TA
(en)
|
2012-05-22 |
2014-12-30 |
Idenix Pharmaceuticals Inc |
D-amino acid compounds for liver disease
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
SI2882737T1
(sl)
|
2012-08-09 |
2019-05-31 |
Celgene Corporation |
Trdna oblika (S)-3-(4-((4-morfolinometil)benzil)oksi-1-oksoizoindolin-2-il) piperidin-2,6-dion hidroklorida
|
RS60416B1
(sr)
|
2012-08-09 |
2020-07-31 |
Celgene Corp |
Lečenje imunoloških i zapaljenskih bolesti
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
WO2014039748A1
(en)
|
2012-09-07 |
2014-03-13 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide ccr3 antagonists
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
TR201809048T4
(tr)
|
2012-10-08 |
2018-07-23 |
Centre Nat Rech Scient |
Hcv enfeksiyonu için 2'-kloro nükleosit analogları.
|
US20140112886A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
RS58023B2
(sr)
|
2012-11-01 |
2021-12-31 |
Infinity Pharmaceuticals Inc |
Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
EP2920195A1
(en)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
CA2892227C
(en)
|
2012-11-30 |
2020-12-15 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
NOVEL DERIVATIVES OF METHYSERGIDE
|
WO2014110305A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
EP2970358B1
(en)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
AU2014273946B2
(en)
|
2013-05-30 |
2020-03-12 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
KR20160055170A
(ko)
|
2013-08-30 |
2016-05-17 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 아세트아미드 화합물 및 이의 사용 방법
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US9700549B2
(en)
|
2013-10-03 |
2017-07-11 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
JP6466924B2
(ja)
|
2013-10-04 |
2019-02-06 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環式化合物及びその使用
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
AU2014354775A1
(en)
|
2013-11-27 |
2016-05-19 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of liver cancer
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
CN103746201B
(zh)
*
|
2013-12-18 |
2016-04-20 |
宁波意欧迅网络通信有限公司 |
高频数据插头和电子配线线缆
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
DK3119397T3
(da)
|
2014-03-19 |
2022-03-28 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
|
US10202398B2
(en)
|
2014-03-20 |
2019-02-12 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
MX2016012097A
(es)
|
2014-03-20 |
2017-04-27 |
Capella Therapeutics Inc |
Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
|
AU2015243437B2
(en)
|
2014-04-09 |
2019-08-29 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins useful for the treatment of pain
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
EP3444011A1
(en)
|
2014-05-12 |
2019-02-20 |
Conatus Pharmaceuticals, Inc. |
Treatment of the complications of chronic liver disease with emricasan
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
EA034691B1
(ru)
|
2014-06-19 |
2020-03-06 |
Ариад Фармасьютикалз, Инк. |
Гетероарильные соединения для ингибирования киназ
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
US20170319548A1
(en)
|
2014-09-12 |
2017-11-09 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
KR20210142781A
(ko)
|
2014-10-21 |
2021-11-25 |
다케다 야쿠힌 고교 가부시키가이샤 |
결정 형태의 5-클로로-n4-[2-(디메틸포스포릴)페닐]-n2-{2-메톡시-4-[4-(4-메틸피페라진-1-일)피페리딘-1-일]피리미딘-2,4-디아민
|
US20170354639A1
(en)
|
2014-10-24 |
2017-12-14 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
MY191736A
(en)
|
2014-12-23 |
2022-07-13 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
CN107428745A
(zh)
|
2015-01-20 |
2017-12-01 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
EP3247357A4
(en)
|
2015-01-20 |
2018-07-11 |
Xoc Pharmaceuticals, Inc |
Isoergoline compounds and uses thereof
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
US20190015396A1
(en)
|
2015-06-23 |
2019-01-17 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
DK3277842T5
(da)
|
2015-08-17 |
2020-08-31 |
Kura Oncology Inc |
Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer
|
CN108473503A
(zh)
|
2015-09-30 |
2018-08-31 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
PT3368534T
(pt)
|
2015-10-30 |
2021-03-09 |
Neurocrine Biosciences Inc |
Ditosilato de valbenazina e polimorfos do mesmo
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
PT3394057T
(pt)
|
2015-12-23 |
2022-04-21 |
Neurocrine Biosciences Inc |
Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
|
SG11201805480TA
(en)
|
2015-12-31 |
2018-07-30 |
Conatus Pharmaceuticals Inc |
Methods of using caspase inhibitors in treatment of liver disease
|
EP3808346B1
(en)
|
2016-01-08 |
2023-07-19 |
Celgene Corporation |
Antiproliferative compounds for use in the treatment of leukemia
|
US10189808B2
(en)
|
2016-01-08 |
2019-01-29 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
JP6880037B2
(ja)
|
2016-01-08 |
2021-06-02 |
セルジーン コーポレイション |
がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
AU2017250086A1
(en)
|
2016-04-11 |
2018-09-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
ES2912921T3
(es)
|
2016-04-29 |
2022-05-30 |
Fgh Biotech Inc |
Compuestos de pirazol disustituidos para el tratamiento de enfermedades
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
AU2017323521B9
(en)
|
2016-09-07 |
2022-02-17 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
AU2017326558B2
(en)
|
2016-09-19 |
2022-01-06 |
Mei Pharma, Inc. |
Combination therapy
|
KR20190082247A
(ko)
|
2016-11-03 |
2019-07-09 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
CA3042055A1
(en)
|
2016-11-09 |
2018-05-17 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
CANCER TREATMENT METHODS
|
US20200078352A1
(en)
|
2016-12-02 |
2020-03-12 |
Neurocrine Biosciences, Inc. |
Use of Valbenazine for Treating Schizophrenia or Schizoaffective Disorder
|
SG11201906883SA
(en)
|
2017-01-27 |
2019-08-27 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
KR102003179B1
(ko)
|
2017-02-21 |
2019-07-23 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
CN110799192A
(zh)
|
2017-03-27 |
2020-02-14 |
加利福尼亚大学董事会 |
治疗癌症的组合物和方法
|
KR20200012833A
(ko)
|
2017-03-29 |
2020-02-05 |
사이트원 테라퓨틱스, 인코포레이티드 |
통증 치료용 11,13-개질된 색시톡신
|
CN110914276A
(zh)
|
2017-03-29 |
2020-03-24 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
JP7212956B2
(ja)
|
2017-05-19 |
2023-01-26 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置用のピロロピリジン-アニリン化合物
|
MX2019013562A
(es)
|
2017-05-19 |
2020-08-03 |
Nflection Therapeutics Inc |
Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
|
BR112019025420A2
(pt)
|
2017-06-01 |
2020-06-16 |
Xoc Pharmaceuticals, Inc. |
Compostos policíclicos e usos destes
|
JP7325400B2
(ja)
|
2017-08-07 |
2023-08-14 |
クラ オンコロジー, インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いてがんを治療する方法
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2019060322A2
(en)
|
2017-09-21 |
2019-03-28 |
Neurocrine Biosciences, Inc. |
HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
|
WO2019071021A2
(en)
|
2017-10-04 |
2019-04-11 |
The Regents Of The University Of California |
IMMUNOMODULATORY OLIGOSACCHARIDES
|
CN116492340A
(zh)
|
2017-10-10 |
2023-07-28 |
纽罗克里生物科学有限公司 |
施用某些vmat2抑制剂的方法
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
US11701334B2
(en)
|
2018-01-10 |
2023-07-18 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
WO2019139871A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
BR112020024018A2
(pt)
|
2018-06-14 |
2021-02-23 |
Neurocrine Biosciences Inc. |
compostos inibidores de vmat2, composições e métodos relacionados a eles
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
KR20210044817A
(ko)
|
2018-08-15 |
2021-04-23 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
CN113286591A
(zh)
|
2018-11-01 |
2021-08-20 |
库拉肿瘤学公司 |
用法尼基转移酶抑制剂治疗癌症的方法
|
AU2019383311A1
(en)
|
2018-11-20 |
2021-06-10 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
EP4233865A3
(en)
|
2018-11-20 |
2023-09-27 |
NFlection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
EP3883567A4
(en)
|
2018-11-20 |
2022-07-27 |
NFlection Therapeutics, Inc. |
NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CONDITIONS
|
CA3120336A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
EP3898609A1
(en)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
JP2022514654A
(ja)
|
2018-12-21 |
2022-02-14 |
クラ オンコロジー, インコーポレイテッド |
扁平上皮癌のための治療法
|
WO2020163554A1
(en)
|
2019-02-06 |
2020-08-13 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US11597703B2
(en)
|
2019-03-07 |
2023-03-07 |
Histogen, Inc. |
Caspase inhibitors and methods of use thereof
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
KR20210144778A
(ko)
|
2019-03-29 |
2021-11-30 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
US20220305001A1
(en)
|
2019-05-02 |
2022-09-29 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
CA3146159A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
US11098002B2
(en)
|
2019-07-26 |
2021-08-24 |
Espervita Therapeutics, Inc. |
Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
BR112022004802A2
(pt)
|
2019-09-16 |
2022-08-23 |
Dice Alpha Inc |
Moduladores de il-17a e usos dos mesmos
|
EP4034236A1
(en)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Compounds useful for treating liver diseases
|
EP4037687A4
(en)
|
2019-10-01 |
2023-09-27 |
Molecular Skin Therapeutics, Inc. |
BENZOXAZINONE COMPOUNDS AS DUAL KLK5/7 INHIBITORS
|
US11529331B2
(en)
|
2020-05-29 |
2022-12-20 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
|
WO2021257828A1
(en)
|
2020-06-18 |
2021-12-23 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
EP4196482A1
(en)
|
2020-08-14 |
2023-06-21 |
SiteOne Therapeutics, Inc. |
Non-hydrated ketone inhibitors of nav1.7 for the treatment of pain
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
EP4284377A1
(en)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Methods for the treatment of fibrotic disease
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
IL305752A
(en)
|
2021-03-10 |
2023-11-01 |
Dice Molecules Sv Inc |
INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
US20230303580A1
(en)
|
2022-03-28 |
2023-09-28 |
Isosterix, Inc. |
Inhibitors of the myst family of lysine acetyl transferases
|
TW202342070A
(zh)
|
2022-03-30 |
2023-11-01 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
US20230416741A1
(en)
|
2022-05-05 |
2023-12-28 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
US20240158370A1
(en)
|
2022-09-09 |
2024-05-16 |
Innovo Therapeutics, Inc. |
CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|